The size of the BioSurgery Market in LATAM is valued at USD 3.08 billion in 2022 and estimated to be growing at a CAGR of 9.74%, to reach USD 4.91 billion by 2027.
Biosurgery aid in the post-surgical care of patients or in the field of orthopedics and in the process of hard tissue regeneration in ortho-biologics as well. Most biosurgery products work on the principle of facilitating homeostasis and tissue healing in surgery.
Various synthetic and biologic products like anti-adhesive agents, homeostatic agents, surgical sealing agents & bone graft substitutes are used in the recovery of patients during and after complex and expensive surgical procedures. They work on the principle of accelerating the process of healing or provide faster wound sealing reducing blood loss during surgeries.
The major driver of the Latin America Bio Surgery market is the increased clearance of biosurgery products by regulatory authorities. This along with factors such as rising number of surgeries, increasing geriatric populations, lifestyle changes and rising need for effective blood loss management bolster the market growth in the region.
However, there are little-to-no reimbursements for biosurgery products and the costs associated with it are generally too high to be utilized by the common public. This along with the rising costs of surgical procedures in general acts as restraints for the market.
This research report on the Latin America BioSurgery Market has been segmented and sub-segmented into the following categories.
Noteworthy companies playing a dominant role in the Latin American Biosurgery Market profiled in this report are Baxter International, C.R. Bard, Johnson & Johnson, Covidien plc., Getinge Group, B. Braun Melsungen AG, Cryolife Inc., Stryker Corporation, Hemostasis LLC., and Sanofi Group.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]